Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Sep 1;202(5):773-774.
doi: 10.1164/rccm.202004-1399LE.

Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?

David A Lipson  1   2 , Mark T Dransfield  3 , MeiLan K Han  4
Affiliations
Comment

Reply to Suissa: Mortality in IMPACT: Confounded by Asthma?

David A Lipson et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, et al. IMPACT Investigators. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201:1508–1516. - PMC - PubMed
    1. Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48:320–330. - PubMed
    1. Martinez FJ, Han MK, Allinson JP, Barr RG, Boucher RC, Calverley PMA, et al. At the root: defining and halting progression of early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197:1540–1551. [Published erratum appears in Am J Respir Crit Care Med 198:1463.] - PMC - PubMed
    1. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. IMPACT Investigators. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680. - PubMed
    1. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. FLAME Investigators. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–2234. - PubMed